市場調查報告書
商品編碼
1401985
2030 年心室輔助裝置市場預測:按產品類型、流量類型、設計、應用、最終用戶和地區進行的全球分析Ventricular Assist Device Market Forecasts to 2030 - Global Analysis By Product Type, Type Of Flow, Design, Application, End User and By Geography |
根據 Stratistics MRC 的數據,2023 年全球心室輔助裝置市場規模為 12.9 億美元,預計預測期內複合年成長率為 12.8%,到 2030 年將達到 30.1 億美元。
一種稱為心室輔助裝置 (VAD) 的機械幫浦被插入體內或體外,以幫助虛弱或故障的心臟將血液泵送到全身。這些設備主要用作心臟移植的橋樑,為不適合移植的患者提供目的地治療,或者在某些情況下,作為嚴重心臟衰竭患者康復的橋樑。
根據世界衛生組織(WHO)2021年估計,全球每年有1,790萬人死於心血管疾病。這佔世界死亡人數的 35%。此外,85% 的心血管疾病死亡是由於心臟病和中風造成的。
慢性病快速增加
進展為心臟衰竭的長期疾病的增加是推動心室輔助裝置需求的因素之一。心臟衰竭可由許多慢性疾病引起,包括糖尿病、高血壓和冠狀動脈疾病。因此,更多的患者將需要先進的心臟治療。隨著導致心臟衰竭的慢性疾病變得越來越普遍,心臟衰竭的治療變得更加長期和深入。這意味著更多的患者將無限期地需要心臟衰竭治療,或不會成為心臟移植的候選者,從而推動市場成長。
高成本
心室輔助裝置治療費用高昂,包括後續治療、外科手術、植入後護理和裝置使用費,可能會限制患者的使用。由於費用過高,財務限制可能會阻止某些人接受這種挽救生命的治療。不同地區和國家的衛生保健系統和經濟狀況的差異可能導致獲得這種治療方法的機會有差異。此外,在醫療基礎設施薄弱或財政資源有限的地區,可能很難接觸到需要這種治療方法的人,這阻礙了市場的成長。
器官衰竭的風險增加
高齡化、生活方式的改變和更頻繁的慢性疾病正在增加器官衰竭的可能性,尤其是心臟衰竭,增加了對心室輔助裝置和其他先進心臟輔助性治療的需求。由於器官衰竭,尤其是心臟衰竭的風險增加,更多的人面臨嚴重心臟疾病的風險。患者群的擴大增加了需要這種療法來治療晚期心臟衰竭的人數。
設備可靠性和耐用性降低
患者和醫生對選擇心室輔助裝置治療的信心可能會受到對心室輔助裝置壽命和可靠性的擔憂的影響。對設備故障或故障的恐懼可能會使患者猶豫或不願意選擇這種治療方法,這可能會對患者的可接受性產生負面影響。此外,旨在推進心室輔助裝置技術的研發計劃的投資可能會受到對裝置可靠性和耐用性的持續擔憂的影響。缺乏資金和缺乏開發新產品的動力可能會阻礙該行業的創新,從而抑制市場成長。
在疫情高峰期,許多醫院和醫療機構在分配資源、優先處理緊急病例和限制不必要的治療方面面臨挑戰。心室輔助裝置植入和定期後續觀察等選擇性手術被推遲或推遲,這可能對市場產生了暫時的影響。全球供應鏈(包括生產和分銷)的中斷也可能影響了這些零件、設備和相關機械的採購和運輸。這些不便會影響心室輔助裝置購買和安裝的時機。
在預測期內,右心室輔助循環裝置領域預計將是最大的。
右心室輔助裝置是心室輔助裝置(VAD)的一種,專門用於支撐心臟的右心室,右心室輔助裝置(RVAD),因此右心室輔助裝置細分市場正在經歷良好的成長。這將會實現。儘管 RVAD 通常側重於輔助心臟的右側,但其他心室輔助裝置旨在輔助左心室(左心室輔助裝置,LVAD)或雙心室(BiVAD)。心室輔助裝置正在進行的研究和技術開發的目標是改善患者的治療結果、減少問題並增強 RVAD 的耐用性,同時解決右心室維護特有的問題。
植入式心室輔助裝置預計在預測期內將經歷最高的複合年成長率
植入式心室輔助裝置領域預計在預測期內複合年成長率最高。稱為植入式心室輔助裝置 (VAD) 的機械幫浦會透過手術插入體內,以幫助心臟泵血。這些設備為嚴重心臟衰竭或等待心臟移植的患者提供協助,是心室輔助設備市場不可或缺的一部分。它可以改善嚴重心臟衰竭患者的生活品質,增強運動能力,減輕心臟衰竭症狀,延長存活期。
由於高齡化、生活方式的改變以及心血管疾病發病率的增加,心臟衰竭在該地區變得普遍,預計亞太地區將在預測期內佔據最大的市場佔有率。由於心臟衰竭患者數量不斷增加,對心室輔助裝置作為治療選擇的需求不斷增加。亞太地區各國正在投資擴大其醫療基礎設施,包括現代化尖端心臟護理設施。許多領先的醫療設備製造商都致力於進入和發展亞太地區的這個市場。
預計歐洲在預測期內的複合年成長率最高,因為與世界許多其他地區一樣,心臟衰竭在歐洲變得越來越普遍。隨著心臟衰竭患者數量的不斷增加,對心室輔助裝置作為晚期心臟衰竭患者治療選擇的需求也越來越大。此外,該技術已改進,現已在歐洲市場上銷售。持續的技術創新旨在改善患者的治療效果,減少與心室輔助裝置治療相關的問題,並生產更緊湊、堅固和有效的設備,從而推動市場成長。
According to Stratistics MRC, the Global Ventricular Assist Device Market is accounted for $1.29 billion in 2023 and is expected to reach $3.01 billion by 2030 growing at a CAGR of 12.8% during the forecast period. A mechanical pump called a Ventricular Assist Device (VAD) is inserted either within or outside the body to help a weak or failing heart pump blood throughout the body. These devices are mostly used as a bridge to heart transplantation, destination treatment for patients not suitable for transplantation, or, in certain circumstances, as a bridge to recovery in patients with severe heart failure.
According to the World Health Organization 2021, an estimated 17.9 million people die due to cardiovascular diseases worldwide, each year. This represents 35% of global deaths. Additionally, 85% of these cardiovascular disease deaths are due to heart attack and stroke.
Surge in the prevalence of chronic conditions
An increase in long-term illnesses that lead to advanced heart failure is one factor driving up demand for ventricular assist device. Heart failure can be caused by a number of chronic illnesses, including diabetes, hypertension, and coronary artery disease. As a result, more individuals will need sophisticated cardiac care. Heart failure care may need to be longer and more intensive if chronic diseases that contribute to heart failure are more common. This may mean that more patients may need this therapy indefinitely, or that more patients who are not candidates for heart transplantation will need thus driving the growth of the market
High cost
Patients' access may be restricted by the high cost of ventricular assist device therapy, which includes follow-up therapies, surgical procedures, post-implantation care, and device fees. Financial limitations may impede certain persons from accessing this life-saving therapy because of its exorbitant expenses. Variations in healthcare systems and economic situations among various areas or nations may give rise to disparities in the accessibility of this treatment. Moreover, this treatment may be difficult to get to those in need in areas with a poor healthcare infrastructure or low financial resources which hamper the market growth.
Increasing risks of organ failures
Ventricular Assist Device and other advanced cardiac support therapies are in greater demand as the chances of organ failures, particularly cardiac failure, and rise owing to aging populations, changing lifestyles, and the frequency of chronic illnesses. An increasing number of people are at risk for serious cardiac disorders due to the rising risks of organ failure, particularly heart failure. The number of people who would need this treatment to treat advanced heart failure rises as a result of this patient pool expansion.
Compromised device reliability and durability
Patients' and doctors' confidence in selecting ventricular assist device therapy may be impacted by worries regarding the longevity and dependability of the device. Fear of device failure or malfunction may cause patients to hesitate or be reluctant to choose this treatment, which may have an adverse effect on patient acceptability. Furthermore, investment in R&D projects targeted at advancing VAD technology may be impacted by enduring worries about the dependability and durability of the devices. Innovation in the industry may be hampered by a lack of funding or a decline in enthusiasm in creating new gadgets impeding the market growth.
Many hospitals and healthcare institutions encountered difficulties in allocating resources, giving priority to urgent cases, and curtailing non-essential treatments during the peak times of the epidemic. It's possible that elective procedures, such as certain ventricular assist device implantations or regular follow-ups, were postponed or delayed, which momentarily affected the market. Disruptions in the worldwide supply chain, including production and delivery, may have affected the accessibility and conveyance of these parts, apparatus, or associated machinery. These hiccups can have an impact on when ventricular assist device are purchased and installed.
The right ventricular assist device segment is expected to be the largest during the forecast period
The right ventricular assist device segment is estimated to have a lucrative growth, as it one kind of Ventricular Assist Device (VAD) made expressly to support the right ventricle of the heart is the Right Ventricular Assist Device (RVAD). The RVAD is generally focused on helping the right side of the heart, while other VADs are designed to support the left ventricle (Left Ventricular support Device, or LVAD) or both ventricles (BiVAD). The goal of ongoing research and technological developments in VADs is to improve patient outcomes, decrease problems, and strengthen the endurance of RVADs while addressing issues unique to sustaining the right ventricle.
The implantable ventricular assist device segment is expected to have the highest CAGR during the forecast period
The implantable ventricular assist device segment is anticipated to witness the highest CAGR growth during the forecast period. Mechanical pumps called Implantable Ventricular Assist Devices (VADs) are surgically inserted within the body to help the heart pump blood. These devices, which provide assistance to those with severe heart failure or that awaiting heart transplantation, are an essential part of the market for ventricular assist devices. The quality of life is enhanced, exercise capacity is boosted, heart failure symptoms are relieved, and patients with severe heart failure have a longer chance of survival due to these devices.
Asia Pacific is projected to hold the largest market share during the forecast period as heart failure is becoming more common in the Asia Pacific area as a result of aging populations, changes in lifestyle, and an increase in cardiovascular disorders. The increased need for ventricular assist device as a therapy option is a result of the rise in heart failure cases. Every nation in the Asia-Pacific area is making investments in the expansion of its healthcare infrastructure, including modernizing its facilities for cutting-edge cardiac treatment. A number of major medical device companies have been concentrating on joining and growing in the Asia Pacific this market.
Europe is projected to have the highest CAGR over the forecast period, because heart failure is becoming more common in Europe, as it is in many other parts of the world. The need for ventricular assist device as a therapy option for individuals with advanced heart failure has increased as a result of the growth in heart failure cases. Moreover, this technology has been improving and is now available in the European market. Constant innovation aims to improve patient outcomes, lower problems related to VAD therapy, and create more compact, robust, and effective devices driving the growth of the market.
Some of the key players profiled in the Ventricular Assist Device Market include Corewave SA, SynCardia Systems, AdjuCor GmbH, Bivacor Inc, LivaNova PLC, Windmill Cardiovascular Systems, Calon Cardio-Technology Ltd, Abiomed, Inc., Fineheart, Abbott Laboratories, Evaheart, Inc.,Berlin Heart GmbH, Carmat SA, Medtronic, Jarvik Heart, Inc., ReliantHeart, Sun Medical Technology Research Corp, Thoratec Corporation and CardiacAssist, Inc
In November 2023, Sun Medical Technology Research Corp. announced that it has received ¥2 billion in funding from Hi-Lex Corporation. The investor will hold 66.7% stake in the company through this transaction.
In September 2023, CorWave announces the grand opening of its manufacturing facility on the banks of the Seine, next to Paris. The company occupies over 2,400m² of production, laboratory, and office space, bringing together its headquarters, R&D center and its first manufacturing facility of almost 1,000m².